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Abstract Random periareolar fine needle aspiration
(RPFNA) and ductal lavage (DL) are research techniques
developed to (1) assess short-term breast cancer risk in asymp-
tomatic women who are at increased risk for breast cancer and
(2) track cytological response to risk reduction strategies.
RPFNA and DL provide minimally invasive methods to re-
peatedly sample epithelial cells and research tools to investi-
gate the biological origins of breast cancer in high-risk
women. This review gives an overview of the strengths and
limitations of both RPFNA and DL for risk assessment and
breast cancer prevention in asymptomatic high-risk women.
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Abbreviations
RPFNA Random periareolar fine needle aspiration
DL Ductal lavage
NAF Nipple aspirate fluid
DCIS Ductal carcinoma in situ
LCIS Lobular carcinoma in situ
Introduction
A woman’s breast cancer risk increases with a first-degree
family history of breast cancer, a Gail risk score of 1.66 or
greater, BRCA1/2 genetic mutation, or the presence of atyp-
ical hyperplasia. There is also evidence that cytological
atypia in breast fluid or breast aspirate increases a woman’s
risk of subsequently developing breast cancer. Random
periareolar fine needle aspiration (RPFNA) and ductal la-
vage (DL) are minimally invasive research tools that are
currently being utilized in a variety of clinical trials to test
for the presence of cytological atypia in high-risk asymp-
tomatic women and to track response to risk reduction
strategies.
Breast cancer incidence has been shown to be reduced in
high-risk cohorts by chemoprevention agents such as tamox-
ifen and through prophylactic surgery [1–4]. However, not all
risk reduction strategies are effective in all women, and more-
over, they may carry potential side effects. Furthermore, our
current clinical trial design makes it difficult to prospectively
identify individual women who are responding to a risk
reduction intervention or a prevention agent. The length of
time required for prospective validation of a predictive
biomarker is not an efficient method for implementing
safe and effective therapeutic treatments. Emerging evi-
dence suggests that combined interventions such as weight
loss, exercise, and a targeted prevention agent may be
more effective than a single intervention alone. As a
result, there is an increasing need to identify biomarkers
that will accurately predict short-term breast cancer risk in
individual women and rapidly assess response to complex
risk reduction strategies.
Biomarkers that vary with risk and response to preven-
tion interventions are referred to as surrogate endpoint bio-
markers [5]. As has been outlined by Fabian et al. [6],
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surrogate endpoint biomarkers should be (1) biologically
and statistically significantly associated with cancer devel-
opment, (2) present in a reasonable proportion of at-risk
individuals, (3) obtainable by minimally invasive proce-
dures, and (4) reversible with prevention interventions that
have been validated to decrease cancer incidence. Many
modalities have been suggested as potential surrogate end-
point biomarkers for breast cancer, including mammograph-
ic density, serum biomarkers, and breast tissue biomarkers
[7–10]. Currently, there is no consensus as to the optimal
surrogate endpoint biomarker.
Breast tissue biomarkers offer the advantage of directly
testing for precancerous changes in the breast. Atypia and
lobular carcinoma in situ (LCIS) are associated with increased
breast cancer risk [11]. Moreover, breast cancer incidence in
women with atypical hyperplasia or LCIS is substantially
reduced after treatment with tamoxifen [1, 2]. However, the
optimal method to repeatedly sample breast tissue remains
controversial. Repeated random core needle biopsies for risk
surveillance and/or for measurement of response to a preven-
tion intervention can cause significant patient discomfort and
are problematic because, unless the biopsy specimens are
obtained from mammographically dense areas, the biopsy is
likely to contain few terminal ductal–lobule units [12]. Nipple
aspirates have shown some promise. However, approxi-
mately 40 % of nipple aspirates are acellular [13]. Here,
we aim to review the strengths and limitations of two
research techniques, RPFNA and DL, that have been
developed to repeatedly sample mammary epithelial cells
and to test surrogate biomarkers of response to prevention
in individual high-risk women.
Random Periareolar Fine Needle Aspiration (RPFNA)
RPFNA is a research technique that was developed by Carol
Fabian, M.D., at the University of Kansas in the mid-1980s to
(1) assess short-term breast cancer risk in women at high risk
for breast cancer and (2) track cytological response to risk
reduction strategies [6, 14]. RPFNA is distinct from diagnostic
FNA. Whereas diagnostic FNA is a standard clinical tech-
nique used to evaluate a clinically identifiable breast mass,
breast RPFNA aims to provide a sampling of cells from the
entire breast of asymptomatic women. Therefore, RPFNA
has the advantage of being able to provide a “snap-shot”
of the whole breast. The strengths of RPFNA are that (1)
the technique can be performed successfully in a majority
of high-risk women (72 %–85 % cell yield) and (2) the
presence of cytological atypia in RPFNA has been shown
to prospectively predict short-term breast cancer risk in
high-risk women [15–17].
In 1986, the late Helene Smith proposed that breast cancer
developed in a “high-risk field” or segment of the breast
containing molecular changes that promote the development
of a malignancy [18]. The existence of a “high-risk field”
remains controversial; however, it is clear that when prolifer-
ative changes are present in the breast, these changes occur in
a multifocal and multicentric pattern [19–21]. RPFNA has the
ability to sample multifocal proliferative changes and to eval-
uate potential “field-effects.” This is particularly useful for
short-term prevention trials because the aim of these studies is
not to biopsy or treat a focal lesion but, rather, to induce
antiproliferative or biomarker changes throughout an at-risk
breast or within a “high-risk field.”
Performance of RPFNA
The breast is anesthetized with 5 cc of 1 % lidocaine, 2–5 cm
from the areola (depending on the size and shape of the
breast), at approximately three and nine o’clock. Nine aspira-
tions are performed per breast, with four aspirations from the
medial skin site and five from the lateral breast site. While
aspirations are guided by the tactile identification of stromal/
ductal tissue, there is no attempt to aspirate a specific location
within the breast (Fig. 1). Aspirated cells contain a mixture of
epithelial, stromal, adipose, and immune cells. These cells are
pooled and placed in modified CytoLytTM with 1 % formalin
for 24 h. Carol Fabian’s group pools cells from both breasts
into a single sample [6], whereas, the Cancer and Leukemia
Group B (CALGB) Prevention Group pools cells from the
right and left breast separately, so as to obtain one sample per
aspirated breast [22•].
Masood Score Evaluation of RPFNA Cytology
RPFNA epithelial cytology is most frequently evaluated on
thin layer cytologic preparation using the Masood Cytology
Index score, a semiquantitative, numeric assessment scale that
is weighted toward epithelial nuclear morphology. A mini-
mum of one epithelial cell cluster with >10 epithelial cells is
required for assessment, and the most abnormal cell cluster is
scored [16, 17]. Epithelial cells are given a score of 1 to 4
points for each of the six morphological characteristics: cell
Fig. 1 Random periareolar fine needle aspiration. The breast is anesthe-
tized with 5 cc of 1 % lidocaine, 2–5 cm from the areola (depending on
the size and shape of the breast), at approximately three and nine o’clock.
Nine aspirations are performed per breast, with four aspirations from the
medial skin site and five from the lateral breast site
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arrangement, pleomorphism, number of myoepithelial cells,
anisonucleosis, nucleoli, and chromatin clumping. The sum of
these points computes the Masood score: <10, nonprolifera-
tive (normal); 11–13, hyperplasia; 14–17, atypia; and >17,
suspicious cytology [16, 17]. The numbers of epithelial cells
are quantified and classified as <10 cells (insufficient), 10–
100 cells, 101–500 cells, 501–1,000 cells, 1,001–5,000 cells,
and >5,000 cells. The number of epithelial cells increases with
the degree of cytological atypia; epithelial cell yield ranges
from (1) 104 to 5×106 (Masood 11–13), (2) 106 to 5×108
(Masood 14–17), and (3) 107 to 109 (Masood >17). Accord-
ingly, epithelial cytology from repeat samples possibly pro-
vides the ability to examine risk biomarkers and to
prospectively predict the subsequent development of breast
cancer.
Predictive Ability of RPFNA to Prospectively Identify Short
Term Breast Cancer Risk
In 2000, Carol Fabian conducted a single institution study
that demonstrated that cytological atypia in RPFNA inde-
pendently predicted for an increase in breast cancer risk in
high-risk women [6]. In this trial, 480 women at increased
risk for breast cancer on the basis of (1) family history of
breast cancer, (2) a prior diagnosis of breast cancer, or (3)
precancerous biopsy prospectively underwent RPFNA.
Investigators tested for the ability of cytological atypia in
the initial RPFNA aspiration and Gail risk score to prospec-
tively predict the subsequent development of breast cancer.
At a 45 months follow-up, 20 women developed breast
cancer. Of these, there were 7 DCIS and 13 invasive breast
cancers. Multiple logistic regression and Cox proportional
hazards analysis demonstrated that either the presence of
cytological atypia in the initial RPFNA or a 10-year Gail
projected an increased probability of developing breast can-
cer. The presence of cytological atypia in RPFNA predicted
for a 5.6-fold increase in the subsequent development of
breast cancer. This study supported the use of cytological
atypia in RPFNA as a marker for high-risk benign lesions in
high-risk women and supported the use of RPFNA in sub-
sequent risk assessment and prevention studies [6].
Advantages and Limitations of RPFNA
RPFNA has the advantages of being inexpensive, performed
in a clinic exam room, and repeatable, allowing for the serial
assessment of predictive biomarkers. The majority of
RPFNA aspirates in high-risk premenopausal and perime-
nopausal women are cellular [23, 24]. As was described
above, the study of Fabian et al. prospectively validated
the use of cytological atypia in RPFNA as a surrogate risk
marker in high-risk women. However, the study of Fabian et
al. has limitations, because it is single-institution study and
cannot be generalized to average-risk women. No study has
been performed to independently confirm the ability of
cytological atypia in RPFNA to predict development of
breast cancer.
While RPFNA has gained in acceptance, its use is limited
by the absence of data with respect to reproducibility in the
technique and interpretation in multiinstitutional studies. To
address these potential limitations, the CALGB Prevention
Group tested the reproducibility of RPFNA in a multiinsti-
tutional cross-sectional study of high-risk women [22•]. In
this study, Masood Cytology Index scores and two cell
count measurements were compared from RPFNA samples
of 63 individual women from five institutions (Duke Uni-
versity, Ohio State University, Roswell Park, University of
Vermont, and Dana Farber Cancer Institute). All investiga-
tors were individually trained to do RPFNA by Carol Fabian
at the University of Kansas. RPFNA was performed on the
same breast, on the same day, by the same investigator,
using separate needles for sequential aspirations. Masood
Cytology Index score and epithelial cell count were
assigned by a blinded, single dedicated cytopathologist
(C.M.Z.). In this study, RPFNA was found to be highly
reproducible with the overall Spearman correlation coeffi-
cients for Masood Cytology score and cell count of .8312
(p<.0001) and .7260 (p<.0001), respectively. Importantly, the
reproducibility of duplicate RPFNA samples from the same
breast was not affected by age, body mass index, 5-year Gail
risk score, menopausal status, BRCA1/2mutation, or the num-
ber of first-degree family members with breast and/or ovarian
cancer [22•].
Studies performed by the CALGB Prevention Group
provide evidence that RPFNA measurements are reproduc-
ible in a cooperative group setting and support the future use
of RPFNA in multiinstitutional prevention trials. However,
there were several limitations to this study. First, the number
of subjects was small (63 women). Second, intraoperator
variability of RPFNA was assessed, but the interoperator
variability was not. The concordance between RPFNA
measurements provided evidence that single operators in
multiple institutions can produce similar results. But this
study did not address whether different operators would
have similar findings in the same woman. Despite the lim-
itations of this study, these data provide important validation
of the reproducibility of RPFNA in a multiinstitutional
cross-sectional study that included cohorts that varied in
demographic composition [22•].
Biomarker and Prevention Studies Utilizing RPFNA
Carol Fabian’s group pioneered the use of RPFNA-based
biomarkers [14]. The first prevention study utilizing RPFNA-
based biomarkers was a double-blind randomized Phase II
chemoprevention trial [14] of alpha-difluoromethylornithine
182 Curr Breast Cancer Rep (2012) 4:180–187
(DFMO) in 119 women at high risk for the development
of breast cancer. Prior to entry, women were required to
have RPFNA cytology that exhibited hyperplasia or hyper-
plasia with atypia, as well as a mammogram and clinical
breast exam judged as not suspicious for breast cancer.
Subjects were randomized to take 0.5 g/m2 DFMO or
placebo p.o. once per day for 6 months, followed by a
repeat RPFNA. Of 119 subjects entered, 96 % completed
the study and were evaluable for the main study end point
[14]. The trial demonstrated no change in RPFNA cytology
and RPFNA-based secondary end points of breast molecu-
lar marker changes (immunocytochemical [IC] expression
of proliferating cell nuclear antigen, p53, and epidermal
growth factor receptor) [14]. Since then, numerous studies
have tested expression of IC and methylation biomarkers in
RPFNA epithelial cytology [14, 19–21, 22•, 23–30]. The
key limitation of all RPFNA-based biomarkers is the het-
erogeneous nature of the cell populations being tested for
specific molecular markers. Recently, investigators have
performed investigator-blinded proteomic profiling of
RPFNA epithelial cytology, using the reverse phase proteo-
mic microarray (RPPM) [31•, 32•]. Up to 60 phosphopro-
teins can be tested in triplicate from 5,000 to 10,000
microdissected RPFNA epithelial cells. These studies pro-
vide the feasibility for tracking phosphoprotein network
signaling in RPFNA cytology in response to risk reduction
strategies, as well as having the potential to increase our
understanding of the earliest events in mammary carcino-
genesis in high-risk women. For example, the RPPM anal-
ysis of epithelial cells from RPFNA samples of nonobese
and obese high-risk women has identified a potential cross-
talk between the receptor tyrosine kinase/mammalian target
of rapamycin signaling with interleukin-6/signal transducer
and activator of transcription signaling in vimentin expres-
sion (unpublished results). Given the established associa-
tions between obesity and adipokines in breast cancer risk,
future proteomic studies will employ serum and breast
RPFNA samples to determine protein expression changes
in the aforementioned signaling networks of high-risk
women undergoing preventative interventions, such as diet
and exercise. While this strategy appears promising, large-
scale adoption of RPPM-RPFNA-based biomarkers will
depend on robustness and reproducibility in investigator
blinded, multiinstitutional trials.
Ductal Lavage (DL)
DL is an experimental technology that utilizes nipple
fluid to identify high-risk and occult malignant lesions
in breast epithelial cells. Initial data from a multicenter
study by Dooley et al. [33] established the safety and
tolerability of the procedure and increased cell yield for
diagnostic evaluation, as compared with nipple aspirates.
Five hundred seven high-risk women were enrolled, in-
cluding 57 % with a history of contralateral breast cancer
and 39 % with a 5-year Gail risk of >1.7 %. NAF
production was possible in 83 % of these women, and
77 % of these women had DL performed, yielding ade-
quate evaluable epithelial cells for cytologic diagnosis in
60 % (299/507) of the patients. The median number of
epithelial cells from evaluable NAF specimens was 120
cells per breast, as compared with 13,500 epithelial cells
per duct with DL. DL was 3.5 times more successful at
producing cytologically evaluable fluid, as compared with
NAF (73 % vs. 22 %, respectively; p<.001), and therefore,
offered a more sensitive method of detecting cellular atypia
[33]. Cytology findings for DL demonstrated inadequate cel-
lular material for diagnosis in 22 %, benign in 54 %, mildly
atypical in 17%, and markedly atypical or malignant in 7% of
patients. The cytopathology results are intended for detection
of epithelial atypia to improve the precision of breast cancer
risk assessment, for detection of occult malignant lesions, and
for potential serial observation in chemoprevention clinical
trials.
Performance of Ductal Lavage
The procedure begins with breast massage and placement of
a suction device to the nipple to identify fluid-yielding ducts
and visualize non-fluid-yielding ducts, which are then can-
nulated with a microcatheter, infused with saline or physio-
logic solution, and then aspirated to collect cells from the
lining of the milk duct (Fig. 2). The location of the lavaged
duct is recorded on a grid to mark the position for future,
repeat lavage. The resultant fluid is then analyzed for cyto-
pathology and categorized as insufficient cellular material
for cytologic diagnosis, benign, mild atypia, severe atypia,
or malignant.
Predictive Ability of Ductal Lavage to Prospectively
Identify Short-Term Breast Cancer Risk
The potential for early detection of breast cancer by DL
was examined in 2004 by Khan et al. [34] in 39 women
with known breast cancer undergoing mastectomy. In this
study, lavage was possible in 36 (82 %) of 44 breasts,
and 31 (70 %) specimens had sufficient cellularity, ex-
cluding specimens that were acellular or contained fewer
than 100 epithelial cells. A high-threshold positive test,
defined as markedly atypical or malignant cytology, was
found in only 13 % (5/38) of cancerous breasts, whereas
a low-threshold positive test that additionally included
mildly atypical cytology was present in 42 % (16/38)
of cancerous breasts. Therefore, the sensitivity for cancer
detection was 13 %–42 % when marked versus mild
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atypia was included, which was attributed to cancer-
containing ducts failing to yield fluid or having benign
or mildly atypical cytology. These results challenge the
previous hypothesis that the breast ducts yielding fluid
on nipple aspiration are the ones most likely to contain
malignant disease. Similar findings were shown in a
study performed at Stanford [35] in which 38 women
underwent the DL procedure with 30 successful attempts
that resulted in 7/30 (23.3 %) with atypical lavage cyto-
pathology. Of the ducts that yielded atypia, five of seven
were from ducts that were non-fluid-yielding on initial
suction aspiration. In addition, only one of seven patients
with atypia in DL fluid had a normal breast MRI and
mammogram screening of the affected breast; however,
six of seven patients with atypia had normal mammo-
grams [35]. Maddux et al. determined that atypia was
equally as likely to be found in both fluid-producing and
dry ducts (19 % vs. 15 %) [36]. However, Wood et al.
found that nipple aspiration fluid was more commonly
expressed in cancerous, as compared with unaffected,
breasts. Overall, sensitivity for detecting marked atypia
or malignant cells in affected breasts was 17 %, which is
comparable to the results in other studies [37].
Advantages and Limitations of Ductal Lavage
DL is a nonsurgical breast epithelial sampling procedure
that was developed to enhance the cellularity and repro-
ducibility for detection of epithelial atypia and for serial
observation in chemoprevention trials. DL offers the abil-
ity to label individual ducts for future recannulation in
order to decrease sample variance in prevention trials, in
addition to identifying the location of any abnormal cells
found by cytopathology. However, the efficacy of DL for
the serial monitoring of breast epithelium was tested for
reproducibility in a study of 23 women, indicating that
fewer than 50 % of women producing atypical DL sam-
ples on the first attempt were found to have atypical
samples on a repeat DL attempt [38]. The reliability of
DL was also tested by Visvanathan et al. [39] and
demonstrated a high rate of inadequate cellular material
for diagnosis with fair cytologic reproducibility and low
participant return rate. Reproducibility was further exam-
ined at Northwestern University in 2008, resulting in
comparable low reproducibility of cell yield and cytolog-
ic findings after a baseline and 6-month repeat DL was
performed in 65 high-risk women. Cytologic diagnosis
was reproducible only in 43 % of patients, concluding
the limited value of DL for serial monitoring in chemo-
prevention trials [40].
Tolerability of DL has been reported as a possible
limitation to its clinical use. The first multiinstitutional
study of DL by Dooley et al. [33] reported the procedure
to be well tolerated without any documented serious
adverse events. Nonetheless, the study states that 51 %
reported DL as less comfortable than mammography, and
44 % experienced breast pain. Another study reported
that DL was not well tolerated, in part due to increased
pain, as compared with mammography and NAF. There
was also a low participant return rate for a repeat DL
[39]. In 2009, the tolerability of DL was again examined
closely among high-risk women and resulted in increased
anticipated, in addition to increased experienced, discom-
fort versus mammogram, MRI, or NAF. Here, 25 % of
women refused to repeat DL [41].
Biomarker and Prevention Studies Utilizing Ductal Lavage
Optimal breast cancer predictive models are combining
biologic and clinical markers to enhance the sensitivity of
DL and identify characteristics of malignant changes
within the breast. For example, DL was utilized for
cancer detection in 2002 by King et al. [42] with 39
paired cases of surgically excised breast lesions and DL
specimens collected prior to surgery. The study showed a
sensitivity of 47 % and a specificity of 79 % in surgical
specimens demonstrating abnormal cytology. Results were
enhanced by the use of molecular markers consisting of
Fig. 2 Ductal lavage. a Nipple fluid aspirator. The procedure begins
with breast massage and placement of a suction device to the nipple to
identify fluid-yielding ducts and visualize non-fluid-yielding ducts. b
Single lumen duct lavage connected to inflow and outflow syringes.
Saline is infused through the inflow syringe and then aspirated to
collect cells from the lining of the milk duct
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fluorescence in situ hybridization with probes for aneusomy
that showed a sensitivity and specificity of 71 % and 89 %,
respectively. Another study that increased the sensitivity of
cytology was demonstrated by Fackler et al. [43], who
utilized quantitative multiplex methylation-specific poly-
merase chain reaction (QM-PCR) to quantitate cumulative
gene promoter hypermethylation in multiple genes that are
markers for breast cancer. As compared with cytology,
QM-PCR doubled the sensitivity of detection of cancer
cells.
To determine the principle that biomarkers of chemo-
prevention agents can be examined using serial DL,
several phase 2 prevention trials were initiated using
tamoxifen. Bhandare et al. [44] assessed the utility of
DL by measuring biomarkers of tamoxifen that included
estrogen receptor α, Ki-67 and cyclooxygenase-2 and
reported baseline findings that acknowledged the feasibil-
ity of cytologic and biomarker studies in 168 patients.
This phase 2 trial included a baseline DL, and the
subject chose tamoxifen or observation, followed by a
repeat DL 6 months later. The final results of this trial
were reported 4 years later with noteworthy limitations:
(1) lack of reproducibility of biomarkers in the observa-
tion group, (2) only 53 % retention of patients from
recruitment to biomarker analysis, and (3) high cost of
DL. In conclusion, DL was labeled as an inefficient
method of biomarker measurement in high-risk women
in this single-institution study [45].
RPFNA versus DL
Comparison of DL and RPFNA as tissue acquisition
methods in early breast cancer prevention trials was
tested prospectively at a single institution by evaluating
sample adequacy and patient tolerability [46]. In this
study, 86 high-risk women (median age of 54.5 years,
75 % postmenopausal) participated in two prospective
phase II chemoprevention trials in which both DL and
RPFNA were done at baseline. Only 31 % of subjects
yielded adequate DL samples for evaluable analysis ver-
sus 96 % for RPFNA, concluding that DL is far less
practical as a biomarker in chemoprevention trials, as
compared with RPFNA. This study also demonstrated
that both procedures were highly tolerable, without the
development of hematoma, infection, or postprocedure
pain requiring analgesic administration [46]. Similar findings
were shown in Zalles et al., with 62 % and 96 % of high-risk
women having a successful procedure with evaluable cyto-
morphology in DL and RPFNA, respectively [16]. Both stud-
ies demonstrated that RPFNA was more likely to yield
evaluable samples, but each method offered similar cytology
results when adequate samples were provided [16, 46].
Evaluation of the cost effectiveness with RPFNA and
DL in stratifying women for breast cancer preventive
interventions was studied in 2004 and demonstrated ef-
fective means to motivate women at high risk for breast
cancer to take tamoxifen if atypia were found. In this study,
RPFNAwas found to be both less expensive and more likely
to produce an evaluable specimen, when compared with DL
[47]. Furthermore, attempted DL has been dependent on the
successful production of NAF for multiple studies, but when
compared with concordant RPFNA specimens, atypical cells
were observed in women with no NAF or an acellular lavage
specimen [48]. Therefore, the lack of production of NAF does
not exclude cytological atypia, and another means of screen-
ing for breast cancer is necessary.
Conclusions
Currently, we lack agents to prevent estrogen receptor-
negative (ER−) breast cancer. Awealth of targeted inhibitors
are undergoing clinical testing for the treatment of ER(−)
breast cancer. However, in order to effectively test targeted
agents for prevention, we first need biomarkers to identify
women who have the highest likelihood of response. Strat-
egies to rapidly test for response and resistance are also
needed.
The past 20 years have focused on developing single bio-
markers. However, it is clear that normal mammary gland
homeostasis requires the coordinated regulation of phospho-
protein signaling networks (rather than single proteins). Cur-
rently, we lack an understanding of the biology of breast cancer
initiation. The combination of RPFNA or DL with high-
throughput proteomic profiling holds promise for investigating
whether dysregulation of interconnected signaling networks
predicts cancer initiation and progression. This approach may
also allow for rapid tracking of response to complex risk
reduction interventions.
Low-toxicity targeted agents are potentially useful in the
prevention of ER(−) breast cancer. However, emerging ev-
idence suggests that some targeted agents, due to their
specificity, may have unanticipated mechanisms of resis-
tance [49]. Recently, it was shown that women receiving
lapatinib for invasive breast cancer developed resistance via
paradoxical activation of quiescent signaling pathways. Sup-
pression of ErbB2-signaling by lapatinib in ER(−) breast
cancer resulted in activation of FOXO3a and caveolin-1,
leading to activation of ER-signaling [50]. This result was
unexpected and highlights the importance of directly testing
for protein signaling inmammary cytology, rather than relying
on indirect markers of response, during administration of
targeted agents. The combination of RPPM with RPFNA or
DL in multiple biomarker development and validation may
not only serve to explain the underlying pathology of breast
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cancer subtypes, but also directly test whether risk reduction
strategies benefit individual women.
Disclosure No potential conflicts of interest relevant to this article
were reported.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for
prevention of breast cancer: report of the National Surgical Adju-
vant Breast and Bowel Project P-1 Study. J Natl Cancer Inst.
1998;90:1371–88.
2. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen
vs raloxifene on the risk of developing invasive breast cancer and
other disease outcomes: the NSABP study of tamoxifen and ralox-
ifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.
3. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral
prophylactic mastectomy in women with a family history of breast
cancer. N Engl J Med. 1999;340:7784.
4. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after
bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
J Natl Cancer Inst. 1999;91:1475–9.
5. Kelloff GJ, Boone CW, Crowell JA, et al. Risk biomarkers and
current strategies in chemopreventive drug development. J Cell
Biochem Suppl. 1996;25:1–14.
6. Fabian CJ, Kimler BF, Zalles CM, et al. Short-term breast cancer
prediction by random periareolar fine-needle aspiration cytology
and the Gail risk model. J Natl Cancer Inst. 2000;92:1217–27.
7. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and
breast cancer risk: effects with time, age, and menopause status. J
Natl Cancer Inst. 1995;87:1622–9.
8. Jernstrom HC, Olsson H, Borg A. Reduced testosterone, 17 beta-
oestradiol and sexual hormone binding globulin, and increased
insulin-like growth factor-1 concentrations, in healthy nulligravid
women aged 19–25 years who were first and/or second degree
relatives to breast cancer patients. Eur J Cancer Prev. 1997;6:330–40.
9. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concen-
trations of insulin-like growth factor-I and risk of breast cancer.
Lancet. 1998;351:1393–6.
10. Allred DC, Hilsenbeck SG. Biomarkers in benign breast tissue
disease: risk factors for breast cancer [editorial]. J Natl Cancer
Inst. 1998;90:1247–8.
11. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer
associated with atypical hyperplasia of lobular and ductal types.
Cancer Epidemiol Biomarkers Prev. 1997;6:297–301.
12. Mansoor S, Ip C, Stomper C. Yield of terminal ductal lobule units
(TLDU) in normal breast stereotactic core biopsy specimens:
implications of biomarker studies. Breast J. 2000;6:220–4.
13. Sauter ER, Ross E, Daly M, et al. Nipple aspirate fluid: a promis-
ing non-invasive method to identify cellular markers of breast
cancer risk. Br J Cancer. 1997;76:494–501.
14. Fabian CJ, Kimler BF, Brady DA, et al. A phase II breast cancer
chemoprevention trial of oral alpha-difluoromethylornithine:
breast tissue, imaging, and serum and urine biomarkers. Clin
Cancer Res. 2002;8:3105–17.
15. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities
for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J
Hum Genet. 1998;62:145–58.
16. Zalles CM, Kimler BF, Kamel S, et al. Cytology patterns in
random aspirates from women at high and low risk for breast
cancer. Breast J. 1995;1:343–9.
17. Masood S, Frykberg ER, McLellan GL, et al. Prospective evalua-
tion of radiologically directed fine-needle aspiration biopsy of
nonpalpable breast lesions. Cancer. 1990;66:1480–7.
18. Deng GR, Lu Y, Zlotnikov G, et al. Loss of heterozygosity in normal
tissue adjacent to breast carcinoma. Science. 1996;274:2057–9.
19. Bean GR, Scott V, Yee L, et al. Retinoic acid receptor-beta2
promoter methylation in random periareolar fine needle aspiration.
Cancer Epidemiol Biomarkers Prev. 2005;14:790–8.
20. Bean GR, Kimler BF, Seewaldt VL. Long-term raloxifene in a woman
at high risk for breast cancer. N Engl J Med. 2006;355:1620–2.
21. Bean GR. Ibarra Drendall C, Goldenberg VK, et al. Hyper-
methylation of the breast cancer-associated gene 1 promoter
does not predict cytologic atypia or correlate with surrogate
end points of breast cancer risk. Cancer Epidemiol Biomarkers
Prev. 2007;16:50–6.
22. • Ibarra-Drendall C, Wilke LG, Zalles C, et al. Reproducibility of
random periareolar fine needle aspiration in a multi-institutional
Cancer and Leukemia Group B (CALGB) cross-sectional study.
Cancer Epidemiol Biomarkers Prev. 2009;18:1379–85. This 5-
institutional study demonstrates for the first time that the surrogate
endpoints Masood cytology index score and cell count in the dupli-
cate RPFNA samples from the same breast of each high-risk woman
are highly reproducible (Spearman correlation coefficients of .831
and .726, respectively)..
23. Khan SA, Masood S, Miller L, et al. Random fine needle aspira-
tion of the breast of women at increased breast cancer risk and
standard risk controls. Breast J. 1998;4:420–5.
24. Fabian CJ, Kamel S, Zalles C, et al. Identification of a chemo-
prevention cohort from a population of women at high risk for
breast cancer. J Cell Biochem Suppl. 1996;25:112–22.
25. Khan QJ, Kimler BF, O'Dea AP, et al. Mammographic density
does not correlate with Ki-67 expression or cytomorphology in
benign breast cells obtained by random periareolar fine needle
aspiration from women at high risk for breast cancer. Breast
Cancer Res. 2007;9:R35.
26. Goldenberg V, Seewaldt VL, Scott V, et al. Atypia in random
periareolar fine needle aspiration affects the decision of high-risk
women to take tamoxifen for breast cancer chemoprevention.
Cancer Epidemiol Biomarkers Prev. 2007;16:1032–43.
27. Seewaldt VL, Goldenberg V, Jones L, et al. Overweight and obese
perimenopausal and postmenopausal women exhibit increased ab-
normal mammary epithelial cytology. Cancer Epidemiol Bio-
markers Prev. 2007;16:613–6.
28. Bean GR, Bryson AD, Pilie PG, et al. Morphologically normal-
appearing mammary epithelial cells obtained from high-risk wom-
en exhibit methylation silencing of INK4a/ARF. Clin Cancer Res.
2007;13:6834–41.
29. Baker JC, Ostrander JH, Lem S, et al. ESR1 promoter hyper-
methylation does not predict atypia in random periareolar fine
needle aspiration nor persistent atypia after 12 months tamox-
ifen chemoprevention. Cancer Epidemiol Biomarkers Prev.
2008;17:1884–90.
30. Evron E, DooleyWC, Umbricht CB, et al. Detection of breast cancer
cells by methylation-specific PCR. Lancet. 2001;357:1335–6.
31. • Pilie PG, Ibarra-Drendall C, Troch MM, et al. Protein microarray
analysis of mammary epithelial cells from obese and nonobese
186 Curr Breast Cancer Rep (2012) 4:180–187
women at high risk for breast cancer: feasibility data. Cancer
Epidemiol Biomarkers Prev. 2011;20:476–82. This pilot proteomic
study demonstrates the potential of identifying differentially
expressed proteins from limiting microdissected epithelial cells of
nonobese and obese high-risk women. Preliminary data from such
study suggest that early expression changes in the structural
component of fat—namely, vimentin—may serve as a potential
marker of risk and progression to breast cancer..
32. • Ibarra-Drendall C, Troch MM, Barry WT, et al. Pilot and feasi-
bility study: prospective proteomic profiling of mammary epithe-
lial cells from high-risk women provides evidence of activation of
pro-survival pathways. Breast Cancer Res Treat. 2011 Jun 7. [Epub
ahead of print]. This exploratory study shows that the interlinked
components of mitochondrial apoptosis pathway are highly
expressed in all mammary epithelial cells of high-risk women,
but the delicate balance between proapoptotic and nonapoptotic
proteins may tip the balance to cell survival during the early steps
of mammary carcinogenesis.
33. Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for
detection of cellular atypic in women at high risk for breast cancer.
J Natl Cancer Inst. 2001;93:1624–32.
34. Khan SA, Wiley EL, Rodriguez N, et al. Ductal lavage findings in
women with known breast cancer undergoing mastectomy. J Natl
Cancer Inst. 2004;96:1510–7.
35. Hartman AF, Daniel BL, Kurian AW, et al. Breast magnetic reso-
nance image screening and ductal lavage in women at high genetic
risk for breast carcinoma. Cancer. 2004;100:479–89.
36. Maddux AJ, Ashfaq R, Naftalis E, et al. Patient and duct selection
for nipple duct lavage. Am J Surg. 2004;188:390–4.
37. Wood ME, Stanley MA, Crocker AM, et al. Ductal lavage of
cancerous and unaffected breasts: procedure success rate and can-
cer detection. Acta Cytol. 2009;53:410–5.
38. Johnson-Maddux A, Ashfaq R, Cler L, et al. Reproducibility
of cytologic atypia in repeat nipple duct lavage. Cancer. 2005;
103:1129–36.
39. Visvanathan K, Santor D, Ali SZ, et al. The reliability of
nipple aspirate and ductal lavage in women at increased risk
for breast cancer—a potential tool for breast cancer risk
assessment and biomarker evaluation. Cancer Epidemiol Bio-
markers Prev. 2007;16:950–5.
40. Patil DB, Lankes HA, Nayar R, et al. Reproducibility of ductal
lavage cytology and cellularity over a 6 month interval in high risk
women. Breast Cancer Res Treat. 2008;112:327–33.
41. Loud JT, Beckjord EB, Nichols K, et al. Tolerability of breast
ductal lavage in women from families at high genetic risk of breast
cancer. BMC Womens Health. 2009;9(1):20.
42. King BL, Tsai SC, Gryga ME, et al. Detection of chromosomal
instability in paired breast surgery and ductal lavage specimens by
interphase fluorescence in situ hybridization. Clin Cancer Res.
2003;9:1509–16.
43. Fackler MJ, Malone K, Zhang Z, et al. Quantitative multiplex
methylation-specific PCR analysis doubles detection of tumor cells
in breast ductal fluid. Clin Cancer Res. 2006;12:3306–10.
44. Bhandare D, Nayar R, Bryk M, et al. Endocrine biomarkers in
ductal lavage samples from women at high risk for breast cancer.
Cancer Epidemiol Biomarkers Prev. 2005;14:2620–7.
45. Khan SA, Lankes HA, Patil DB, et al. Ductal lavage is an ineffi-
cient method of biomarker measurement in high-risk women.
Cancer Prev Res. 2009;2:265–73.
46. Arun B, Valero V, Logan C, et al. Comparison of ductal lavage and
random periareolar fine needle aspiration as tissue acquisition
methods in early breast cancer prevention trials. Clin Cancer Res.
2007;13:4943–8.
47. Ozanne EM, Esserman LJ. Evaluation of breast cancer risk assess-
ment techniques: a cost-effectiveness analysis. Cancer Epidemiol
Biomarkers Prev. 2004;13:2043.
48. Sharma P, Klemp JR, Simensen M, et al. Failure of high risk
women to produce nipple aspirate fluid does not exclude detection
of cytologic atypia in random periareolar fine needle aspiration
specimens. Breast Cancer Res Treat. 2004;87:59.
49. XiaW, Bacus S, Hedge P, et al. A model of acquired autoresistance to
a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to
prevent its onset in breast cancer. Proc Natl Acad Sci USA.
2006;103:7795–800.
50. Chen FL, Xia W, Spector NL. Acquired resistance to small molecule
ErbB2 tyrosine kinase inhibitors. Clin Cancer Res. 2008;14:6730–4.
Curr Breast Cancer Rep (2012) 4:180–187 187
